News | August 27, 2021
SEC recommends Phase I clinical trials for Reliance’s Covid-19 vaccine candidate
The company has to approach the DCGI for approval to commence the trials
The company has to approach the DCGI for approval to commence the trials
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
AstraZeneca, Sinopharm and Moderna were part of the study
Proactively engaging with foreign vaccine manufacturers like Moderna, Pfizer etc., to apply for Emergency Use Authorization in India so that these vaccines can be easily imported and made available in India
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Subscribe To Our Newsletter & Stay Updated
